Professor
Vanderbilt University Medical Center
Dr. Xiao-Ou Shu is an Ingram Professor of Cancer Research, Professor in the Department of Medicine at the Vanderbilt University School of Medicine, co-leader for the Cancer Epidemiology Program, and Associate Director for Global Health at the Vanderbilt-Ingram Cancer Center. She is a fellow of American College of Epidemiology, Association for Advancement of Science fellow and an elected member of the American Epidemiology Society. She has been consistently funded by US National Institute of Health since 1996, serving as the principal investigator for more than 26 major research grants and 4 training grants. Dr. Shu has over 38 years of experience in conducting large-scale epidemiological studies on cancer and other chronic diseases. Currently, she serves as the contact PI for two R01/U01 grants focusing on discovery of biomarkers for pancreatic cancer and biliary track cancer. She is also a joint PI for an R01 grant to investigate the role of gut microbiome in colorectal cancer etiology after a bariatric surgery and an UG3/UH3 grant to establish a sarcoma patient cohort for a longitudinal investigation of the contribution of genetic, cancer treatment and lifestyle factors on disease prognosis and survivorship. In addition, she leads the Vanderbilt Genetic and Molecular Epidemiology of Cancer (MEGEC) training program (T32) and the Vanderbilt-Zambia Cancer Research (VZCARE) training grant (D43).She has authored or co-authored more than 1,500 peer-reviewed research papers covering the etiology and prognosis of a wide spectrum of diseases, primarily on cancer, several on diabetes and cardiovascular diseases, and recently extended to aging. She was recognized as a “Highly Cited Researcher” by Thomas Reuters/Clarivate Analytics in 2015, 2016, and again in 2018, and has a H-Index of 154. She was one of the “Best Female Scientists in the United States 2022 Ranking” named by the Research.com. In 2023,
